BridgeBio (BBIO) investor relations material

Executive summary

• Net product revenue for Q2 2026 surged to $222.4M, up from $71.5M in Q2 2025, driven by strong commercial expansion of Attruby and Beyonttra following regulatory approvals in the US, EU, Japan, and UK.

• Three late-stage programs (BBP-418, encaleret, infigratinib) advanced to regulatory review, with two receiving FDA priority review and launches expected upon approval.

• Published new data showing Attruby's direct kidney protection in ATTR-CM, reinforcing clinical differentiation and superiority over tafamidis.

• Closed $1B preferred equity financing post-quarter, boosting cash to $1.7B to support upcoming launches and pipeline expansion.

• Commercial Day scheduled for October 8, 2026, to discuss launch strategies.

Financial highlights

• Total Q2 2026 revenue was $243.7M, up from $110.5M in Q2 2025, mainly due to increased Attruby sales and higher royalty revenue.

• Net loss for Q2 2026 was $152.2M, improved from $181.9M in Q2 2025; net loss per share was $0.78, compared to $0.95 in Q2 2025.

• Operating expenses increased to $350.8M, reflecting higher SG&A and R&D investments.

• Cash, cash equivalents, and marketable securities totaled $720.2M as of June 30, 2026, excluding $1B in July financing.

• Outstanding debt was $2.5B, with deferred royalty obligations of $908.7M.

Outlook and guidance

• Expect continued steady sales growth for Attruby and Beyonttra, driven by first-line market expansion and clinical differentiation.

• Three product launches anticipated in the next 12 months, supported by robust cash position.

• U.S. launches for BBP-418 and encaleret expected upon FDA approval, with PDUFA dates set for November 27, 2026, and May 8, 2027.

• Oral infigratinib U.S. launch anticipated mid-2027, with EU approval expected in the second half of 2027.

• Ongoing investments in R&D and commercialization are projected to drive operating losses for the next several years.